• Asymchem published 2025 annual report, highlighting recovery in CDMO demand with double-digit revenue growth.
• Order backlog reached USD 1.4 billion, supported by rapid expansion in chemical macromolecule CDMO and biological macromolecule CDMO.
• Emerging businesses scaled up, led by peptides and oligonucleotides, with overseas revenue in these segments rising more than 240%.
• Commercial execution broadened with first peptide project moving into commercial supply, while first ADC drug entered commercialization following pre-approval inspection clearance.
• Capacity buildout continued, including peptide synthesis capacity set to rise to 69,000 L by end-2026, while oligonucleotide capacity is projected to reach 180 mol by end-June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asymchem Laboratories Tianjin Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12112606), on April 20, 2026, and is solely responsible for the information contained therein.